UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

41.40 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

February 20, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

February 19, 2025

Via AB Newswire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

February 14, 2025

From UroGen Pharma Ltd.

Via Business Wire

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

February 12, 2025

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

January 30, 2025

From UroGen Pharma Ltd.

Via Business Wire

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

January 22, 2025

From UroGen Pharma Ltd.

Via Business Wire

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

January 15, 2025

From UroGen Pharma Ltd.

Via Business Wire

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗

January 14, 2025

Via Benzinga

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 10, 2025

Via Benzinga

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC

December 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs

December 02, 2024

From UroGen Pharma Ltd.

Via Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

November 26, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

November 06, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

November 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

October 30, 2024

From UroGen Pharma Ltd.

Via Business Wire

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

October 28, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

October 15, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Appoints Chris Degnan as Chief Financial Officer

October 09, 2024

From UroGen Pharma Ltd.

Via Business Wire

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

October 02, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

September 16, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences

August 29, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 14, 2024

From UroGen Pharma Ltd.

Via Business Wire

URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024 ↗

August 13, 2024

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

August 13, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

August 05, 2024

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

June 18, 2024

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.